Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial

IMPORTANCE: The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) randomized clinical trial was stopped early owing to the efficacy of low-dose rivaroxaban plus aspirin in preventing major cardiovascular events. The main reason for early trial termination was the effect o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Neurol
Päätekijät: Perera, Kanjana S., Ng, Kelvin K. H., Nayar, Sumiti, Catanese, Luciana, Dyal, Leanne, Sharma, Mukul, Connolly, Stuart J., Yusuf, Salim, Bosch, Jackie, Eikelboom, John W., Hart, Robert G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2019
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6749537/
https://ncbi.nlm.nih.gov/pubmed/31524941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.2984
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia